CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 1161
Diana Lim, Eric S. Renteria, Drake S. Sime, Young Min Ju, Ji Hyun Kim, Tracy Criswell, Thomas D. Shupe, Anthony Atala, Frank C. Marini, Metin N. Gurcan, Shay Soker, Joshua Hunsberger & James J. Yoo . Bioreactor design and validation for manufacturing strategies in tissue engineering[J]. Journal of Zhejiang University Science D, 2022, 5(1): 43-63.
@article{title="Bioreactor design and validation for manufacturing strategies in tissue engineering",
author="Diana Lim, Eric S. Renteria, Drake S. Sime, Young Min Ju, Ji Hyun Kim, Tracy Criswell, Thomas D. Shupe, Anthony Atala, Frank C. Marini, Metin N. Gurcan, Shay Soker, Joshua Hunsberger & James J. Yoo ",
journal="Journal of Zhejiang University Science D",
volume="5",
number="1",
pages="43-63",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1007/s42242-021-00154-3"
}
%0 Journal Article
%T Bioreactor design and validation for manufacturing strategies in tissue engineering
%A Diana Lim
%A Eric S. Renteria
%A Drake S. Sime
%A Young Min Ju
%A Ji Hyun Kim
%A Tracy Criswell
%A Thomas D. Shupe
%A Anthony Atala
%A Frank C. Marini
%A Metin N. Gurcan
%A Shay Soker
%A Joshua Hunsberger & James J. Yoo
%J Journal of Zhejiang University SCIENCE D
%V 5
%N 1
%P 43-63
%@ 1869-1951
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1007/s42242-021-00154-3
TY - JOUR
T1 - Bioreactor design and validation for manufacturing strategies in tissue engineering
A1 - Diana Lim
A1 - Eric S. Renteria
A1 - Drake S. Sime
A1 - Young Min Ju
A1 - Ji Hyun Kim
A1 - Tracy Criswell
A1 - Thomas D. Shupe
A1 - Anthony Atala
A1 - Frank C. Marini
A1 - Metin N. Gurcan
A1 - Shay Soker
A1 - Joshua Hunsberger & James J. Yoo
J0 - Journal of Zhejiang University Science D
VL - 5
IS - 1
SP - 43
EP - 63
%@ 1869-1951
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1007/s42242-021-00154-3
Abstract: The fields of regenerative medicine and tissue engineering offer new therapeutic options to restore, maintain or improve tissue function following disease or injury. To maximize the biological function of a tissue-engineered clinical product, specific conditions must be maintained within a bioreactor to allow the maturation of the product in preparation for implantation. Specifically, the bioreactor should be designed to mimic the mechanical, electrochemical and biochemical environment that the product will be exposed to in vivo. Real-time monitoring of the functional capacity of tissue-engineered products during manufacturing is a critical component of the quality management process. The present review provides a brief overview of bioreactor engineering considerations. In addition, strategies for bioreactor automation, in-line product monitoring and quality assurance are discussed.
Open peer comments: Debate/Discuss/Question/Opinion
<1>